Search Results - "RALSTON, Sherry"

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate by Phillips, Andrew C, Boghaert, Erwin R, Vaidya, Kedar S, Falls, Hugh D, Mitten, Michael J, DeVries, Peter J, Benatuil, Lorenzo, Hsieh, Chung-Ming, Meulbroek, Jonathan A, Panchal, Sanjay C, Buchanan, Fritz G, Durbin, Kenneth R, Voorbach, Martin J, Reuter, David R, Mudd, Sarah R, Loberg, Lise I, Ralston, Sherry L, Cao, Diana, Gan, Hui K, Scott, Andrew M, Reilly, Edward B

“…Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl…”
Get full text

ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models by Li, Yingchun, Hickson, Jonathan A, Ambrosi, Dominic J, Haasch, Deanna L, Foster-Duke, Kelly D, Eaton, Lucia J, DiGiammarino, Enrico L, Panchal, Sanjay C, Jiang, Fang, Mudd, Sarah R, Zhang, Catherine, Akella, Surekha S, Gao, Wenqing, Ralston, Sherry L, Naumovski, Louie, Gu, Jijie, Morgan-Lappe, Susan E

“…Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway…”
Get full text

Towards in vitro models for reducing or replacing the use of animals in drug testing by Stresser, David M., Kopec, Anna K., Hewitt, Philip, Hardwick, Rhiannon N., Van Vleet, Terry R., Mahalingaiah, Prathap Kumar S., O’Connell, Denice, Jenkins, Gary J., David, Rhiannon, Graham, Jessica, Lee, Donna, Ekert, Jason, Fullerton, Aaron, Villenave, Remi, Bajaj, Piyush, Gosset, James R., Ralston, Sherry L., Guha, Manti, Amador-Arjona, Alejandro, Khan, Kainat, Agarwal, Saket, Hasselgren, Catrin, Wang, Xiaoting, Adams, Khary, Kaushik, Gaurav, Raczynski, Arkadiusz, Homan, Kimberly A.

“…Pharmaceutical companies continue to advocate for the use of in vitro models towards the reduction of animal use in drug discovery and development while…”
Get full text

Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group by Birkebak, Joanne, Buckley, Lorrene A., Dambach, Donna, Musvasva, Eunice, Price, Karen, Ralston, Sherry, Sacaan, Aida

“…Interest in developing combination products to overcome drug resistance and treat complex diseases is growing. However, ambiguity remains around the value of…”
Get full text

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors by Judd, Andrew S, Bawa, Bhupinder, Buck, Wayne R, Tao, Zhi-Fu, Li, Yingchun, Mitten, Michael J, Bruncko, Milan, Catron, Nathaniel, Doherty, George, Durbin, Kenneth R, Enright, Brian, Frey, Robin, Haasch, Deanna, Haman, Sandra, Haight, Anthony R, Henriques, Tracy A, Holms, James, Izeradjene, Kamel, Judge, Russell A, Jenkins, Gary J, Kunzer, Aaron, Leverson, Joel D, Martin, Ruth L, Mitra, Diya, Mittelstadt, Scott, Nelson, Lorne, Nimmer, Paul, Palma, Joann, Peterson, Richard, Phillips, Darren C, Ralston, Sherry L, Rosenberg, Saul H, Shen, Xiaoqiang, Song, Xiaohong, Vaidya, Kedar R, Wang, Xilu, Wang, Jin, Xiao, Yu, Zhang, Haichao, Zhang, Xinxin, Blomme, Eric A, Boghaert, Erwin R, Kalvass, John C, Phillips, Andrew, Souers, Andrew J

“…Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-XL) is associated with drug resistance and disease progression in numerous…”
Get full text

BCL-X L -targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors by Judd, Andrew S, Bawa, Bhupinder, Buck, Wayne R, Tao, Zhi-Fu, Li, Yingchun, Mitten, Michael J, Bruncko, Milan, Catron, Nathaniel, Doherty, George, Durbin, Kenneth R, Enright, Brian, Frey, Robin, Haasch, Deanna, Haman, Sandra, Haight, Anthony R, Henriques, Tracy A, Holms, James, Izeradjene, Kamel, Judge, Russell A, Jenkins, Gary J, Kunzer, Aaron, Leverson, Joel D, Martin, Ruth L, Mitra, Diya, Mittelstadt, Scott, Nelson, Lorne, Nimmer, Paul, Palma, Joann, Peterson, Richard, Phillips, Darren C, Ralston, Sherry L, Rosenberg, Saul H, Shen, Xiaoqiang, Song, Xiaohong, Vaidya, Kedar R, Wang, Xilu, Wang, Jin, Xiao, Yu, Zhang, Haichao, Zhang, Xinxin, Blomme, Eric A, Boghaert, Erwin R, Kalvass, John C, Phillips, Andrew, Souers, Andrew J

“…Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-X ) is associated with drug resistance and disease progression in numerous…”
Get full text

Towards in vitro models for reducing or replacing the use of animals in drug testing by Stresser, David M, Kopec, Anna K, Hewitt, Philip, Hardwick, Rhiannon N, Van Vleet, Terry R, Mahalingaiah, Prathap Kumar S, O'Connell, Denice, Jenkins, Gary J, David, Rhiannon, Graham, Jessica, Lee, Donna, Ekert, Jason, Fullerton, Aaron, Villenave, Remi, Bajaj, Piyush, Gosset, James R, Ralston, Sherry L, Guha, Manti, Amador-Arjona, Alejandro, Khan, Kainat, Agarwal, Saket, Hasselgren, Catrin, Wang, Xiaoting, Adams, Khary, Kaushik, Gaurav, Raczynski, Arkadiusz, Homan, Kimberly A

Get full text

Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451 by ROBERTS, W. Gregory, WHALEN, Pamela M, ATHERTON, James A, RALSTON, Sherry, SZEWC, Ruby, KATH, John C, JING LIN, SODERSTROM, Cathy, TKALCEVIC, George, COHEN, Bruce D, POLLACK, Vince, BARTH, Wayne, SODERSTROM, Erik, HUNGERFORD, Will, UNG, Ethan, MORASKI, Garrett, LYSSIKATOS, Joseph P, WANG, Huifen-F, COOPER, Beth, BAKER, Deborah A, SAVAGE, Douglas, DALVIE, Deepak

“…CP-673,451 is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-beta…”
Get full text

Stereoselective Activation of Dibenzo[a,l]pyrene and Its trans-11,12-Dihydrodiol to Fjord Region 11,12-Diol 13,14-Epoxides in a Human Mammary Carcinoma MCF-7 Cell-Mediated V79 Cell Mutation Assay by Ralston, Sherry L, Coffing, Stephanie L, Seidel, Albrecht, Luch, Andreas, Platt, Karl-Ludwig, Baird, William M

“…Dibenzo[a,l]pyrene (DB[a,l]P) represents the most potent carcinogenic polycyclic aromatic hydrocarbon (PAH) yet discovered. Like other PAHs, DB[a,l]P requires…”
Get full text

The potent carcinogen dibenzo[a,l]pyrene is metabolically activated to fjord-region 11,12-diol 13,14-epoxides in human mammary carcinoma MCF-7 cell cultures by RALSTON, S. L, LAU, H. H. S, SEIDEL, A, LUCH, A, PLATT, K. L, BAIRD, W. M

“…Dibenzo[a,l]pyrene (DB[a,l]P), an environmental hydrocarbon and very potent carcinogen in rodent bioassays, could be activated to DNA-binding intermediates in…”
Get full text

Abstract 867: ABT-165 is a first-in-class therapeutic Dual Variable Domain Immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer by Li, Yingchun, Hickson, Jonathan, Ambrosi, Dominic, Haasch, Deanna, Foster-Duke, Kelly, Eaton, Lucia, Jiang, Fang, Akella, Surekha, Gao, Wenqing, Ralston, Sherry, Gu, Jijie, Morgan-Lappe, Susan

“…The first generation anti-angiogenic drugs designed to block the VEGF/VEGFR pathway lend modest clinical benefit for cancer patients. Other than VEGF, DLL4 is…”
Get full text

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor by JANI, Jitesh P, FINN, Richard S, MORRIS, Joel, MOYER, James D, PUSTILNIK, Leslie R, RAFIDI, Kristina, RALSTON, Sherry, ROSSI, Ann Marie K, STEYN, Stefanus J, WAGNER, Larry, WINTER, Steven M, BHATTACHARYA, Samit K, CAMPBELL, Mary, COLEMAN, Kevin G, CONNELL, Richard D, CURRIER, Nicolas, EMERSON, Erling O, FLOYD, Eugenia, HARRIMAN, Shawn, KATH, John C

“…Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach…”
Get full text

Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol by Stoner, Gary, Casto, Bruce, Ralston, Sherry, Roebuck, Bill, Pereira, Clifford, Bailey, George

“…Indole-3-carbinol (I-3-C) is among the most widely and popularly known antiestrogens. Due to its putative chemopreventive action, I-3-C is being marketed to…”
Get full text

Stereoselective activation of dibenzo[a,l]pyrene to (-)-anti (11R,12S,13S,14R)- and (+)-syn(11S,12R,13S,14R)-11,12-diol-13,14-epoxides which bind extensively to deoxyadenosine residues of DNA in the human mammary carcinoma cell line MCF-7 by Ralston, S L, Seidel, A, Luch, A, Platt, K L, Baird, W M

“…Dibenzo[a,l]pyrene (DB[a,l]P) is an environmental contaminant and a very potent carcinogen. DB[a,l]P exceeds the carcinogenic potency of both benzo[a]pyrene…”
Get more information

Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol by Stoner, Gary, Casto, Bruce, Ralston, Sherry, Roebuck, Bill, Pereira, Clifford, Bailey, George

Get full text

The mechanism of metabolic activation of the very potent carcinogen dibenzo(a,l)pyrene by Ralston, Sherry Lynn

“…Dibenzo (a,l) pyrene (DB (a,l) P) is an environmental polycyclic aromatic hydrocarbon (PAH) and the most potent carcinogen tested in rodent bioassays. As with…”
Get full text

Expression of Cell Cycle Proteins in 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced Mouse Lung Tumors by Sabourin, Carol L. K., Wang, Qian-Shu, Ralston, Sherry L., Evans, Jason, Coate, Jennifer, Herzog, Christopher R., Jones, Sandra L., Weghorst, Christopher M., Kelloff, Gary J., Lubet, Ronald A., You, Ming, Stoner, Gary D.

“…Cyclin D1 dysregulation and differential inactivation of p16INK4a and Rb have been observed in human lung cancer. In chemically induced mouse lung tumors, the…”
Get full text

Professional Assessment and Development by Hatfield, Robert C, Ralston, Sherry

“…It is proposed that in considering teachers' professional development, emphasis should be placed on teacher assessment as an intergral part of the…”
Get more information